-

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November:

  • Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology (INI) Conference on Tuesday, November 7, 2023 at 1:10 pm (EST)
  • Evercore ISI 6th Annual HealthCONx Conference on Thursday, November 30, 2023 at 12:30 pm (EST)

The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Contacts

Incyte
Media
media@incyte.com

Investors
ir@incyte.com

Industry:

Incyte

NASDAQ:INCY
Release Versions
English

Contacts

Incyte
Media
media@incyte.com

Investors
ir@incyte.com

More News From Incyte

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

WILMINGTON, Del.--(BUSINESS WIRE)--Phase 1/2 Multidose Data for VGA039 (Latarcibart) Show Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types...

Incyte to Report Second Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. The schedule for the press release and conference call/webcast is as follows: Q2 2026 Press Release: July 28, 2026, at 7:00 a.m. ET Q2 2026 Conference Call: July 28, 2026, at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13759...

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio...
Back to Newsroom